BSW Wealth Partners Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

BSW Wealth Partners lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,048 shares of the biopharmaceutical company’s stock after buying an additional 335 shares during the quarter. BSW Wealth Partners’ holdings in Gilead Sciences were worth $559,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. State Street Corp boosted its stake in shares of Gilead Sciences by 1.4% during the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock valued at $5,044,795,000 after purchasing an additional 841,776 shares during the period. Wellington Management Group LLP grew its stake in Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares in the last quarter. FMR LLC increased its position in shares of Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Gilead Sciences by 2.1% in the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock valued at $2,302,119,000 after purchasing an additional 574,421 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Gilead Sciences by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company’s stock worth $650,009,000 after purchasing an additional 224,960 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $93.85 on Wednesday. The firm’s fifty day moving average is $91.88 and its two-hundred day moving average is $85.27. The firm has a market cap of $116.96 billion, a price-to-earnings ratio of 1,042.78, a PEG ratio of 1.31 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the company earned $2.29 earnings per share. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. The Goldman Sachs Group upped their target price on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Mizuho upped their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $87.00 to $113.00 in a report on Friday, January 10th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $97.96.

Insider Activity at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 in the last three months. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.